DEFA14A: Glucotrack Urges Shareholder Vote on $20M Equity Deal

Glucotrack, Inc. reconvenes its Special Meeting of Shareholders on November 7, 2025, to vote on a $20 million Equity Purchase Agreement with Sixth Borough Capital Fund LP.

Summary

• Glucotrack, Inc. will reconvene a Special Meeting of Shareholders on November 7, 2025, at 12 p.m. ET.
• Shareholders are encouraged to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund LP.
• The agreement allows Glucotrack to issue more than 20% of its issued and outstanding Common Stock, in compliance with NASDAQ Listing Rule 5635(d).
• The Board of Directors unanimously recommends that shareholders vote FOR all proposals.
• Shareholders of record as of September 23, 2025, are entitled to vote.
• The company is developing a long-term implantable continuous blood glucose monitoring system (CBGM) with a 3-year sensor longevity and minimal calibration, which is currently an Investigational Device.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the need for a capital raise and potential dilution are present, the proactive step to secure $20 million in funding and the unanimous board recommendation for approval are positive indicators for the company's financial stability and continued development efforts.

Positives

• The proposed $20 million Equity Purchase Agreement with Sixth Borough Capital Fund LP provides a significant capital infusion for the company.
• The Board of Directors unanimously recommends a 'FOR' vote, indicating strong internal support for the agreement.
• Securing this funding is crucial for the continued design, development, and commercialization of novel technologies for diabetes management.

Negatives

• The agreement involves issuing more than 20% of the company's common stock, which implies potential dilution for existing shareholders.
• The need for shareholder approval indicates that the funding is not yet secured and depends on the outcome of the vote.

Risks

• Ability to raise additional capital to finance operations (through equity offerings, debt financings, or collaborations).
• Risks related to the receipt and timing of regulatory approvals, including U.S. Food and Drug Administration (FDA) approval.
• Risks associated with patient enrollment in and the conduct of clinical trials.
• Risks concerning future distribution agreements.
• Risks related to the ability to hire and retain qualified personnel, including sales and distribution personnel.
• General risk factors described in Glucotrack's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

Glucotrack is actively developing a long-term implantable continuous blood glucose monitoring system for people with diabetes, designed for 3-year sensor longevity with minimal calibration and no on-body wearable component. This device is currently an Investigational Device, limited by federal law to investigational use.

Management Comments

• Glucotrack strongly encourages all shareholders to vote their shares as soon as possible.
• The Board of Directors unanimously recommends that shareholders vote FOR all proposals.
• Every vote is important, and the Company encourages ALL shareholders to participate to ensure their shares are represented by voting as soon as possible so their votes are tabulated before the meeting date.

Industry Context

Glucotrack operates within the medical technology sector, specifically focusing on diabetes management. The development of a long-term implantable continuous blood glucose monitoring system positions the company in a competitive and evolving market segment aiming to improve the quality of life for people with diabetes by offering less intrusive and more convenient monitoring solutions compared to traditional methods or existing wearable devices.

Stakeholder Impact

• Shareholders: Required to vote on a significant equity issuance, facing potential dilution but also benefiting from the company securing crucial funding for operations and development.
• Company: Securing $20 million in capital is vital for financing operations and advancing its investigational device, impacting its ability to continue development and commercialization efforts.
• Sixth Borough Capital Fund LP: Will become a significant equity holder in Glucotrack upon approval and closing of the agreement.

Next Steps

• Shareholders to cast their votes on the Equity Purchase Agreement by November 7, 2025.
• The Special Meeting of Shareholders will reconvene on November 7, 2025, at 12 p.m. ET.
• If approved, the company will proceed with the issuance of common stock under the $20 million Purchase Agreement.

Key Dates

Recommendation

The filing details a crucial shareholder vote for a $20 million equity purchase agreement, which is vital for the company's operations and development of its investigational device. While securing funding is positive for long-term viability, the vote itself is a procedural step, and the implied dilution warrants a cautious approach. An investor would likely 'hold' pending the outcome of the vote and further operational updates, as this filing primarily addresses a financing mechanism rather than operational performance or a direct investment thesis.

Keywords

Glucotrack, GCTK, Equity Purchase Agreement, Sixth Borough Capital Fund, Shareholder Meeting, Proxy Vote, Capital Raise, Diabetes Technology, Continuous Glucose Monitoring, Medical Technology, NASDAQ Listing Rule 5635(d), SEC Filing